Loring Wolcott & Coolidge Fiduciary Advisors LLP Ultragenyx Pharmaceutical Inc. Transaction History

Loring Wolcott & Coolidge Fiduciary Advisors LLP

$11.1 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$77.92 - $102.4 $7,324 - $9,625	-94 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$92.19 - $115.71 $8,665 - $10,876	94 New	94 $9,000
Q1 2021 Apr 14, 2021	SELL	$106.9 - $167.73 $8,338 - $13,082	-78 Closed	0 $0
Q4 2020 Jan 14, 2021	BUY	$84.4 - $177.39 $6,583 - $13,836	78 New	78 $11,000

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.6M

Call Options Held

520K

Put Options Held

406K

Vanguard Group Inc Valley Forge, PA

9.95M
Shares

$418 Million
0.01% of portfolio
Black Rock Inc. New York, NY

5.6M
Shares

$236 Million
0.01% of portfolio
Sands Capital Management, LLC Arlington, VA

5.12M
Shares

$215 Million
0.91% of portfolio
Wellington Management Group LLP Boston, MA

4.17M
Shares

$175 Million
0.04% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.07M
Shares

$129 Million
0.02% of portfolio

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.95B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.

Account